NASDAQ · CRSP
CRISPR Therapeutics AG
$54.26+$0.15 (+0.28%)
CRISPR Therapeutics AG’s quoted price sits in the lower half of its reported 52-week range, 17.76% below the high.
Loading market information…
NASDAQ · EDIT · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Editas Medicine, Inc.’s quoted price sits in the upper half of its reported 52-week range, 25.63% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Editas Medicine, Inc.’s next earnings report is currently expected on Nov 9, 2026, with estimated earnings per share of -$0.21. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Editas Medicine, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:38 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 12, 2025 | -$0.92-63.13% vs estimate | $4.66M+625.65% vs estimate |
|---|
| Q4 2024 | Mar 5, 2025 | -$0.55-41.03% vs estimate | $30.60M+4,680.01% vs estimate |
|---|
| Q3 2024 | Nov 4, 2024 | -$0.75+1.32% vs estimate | $61.00K-99.79% vs estimate |
|---|
THE ANALYST VIEW
26 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 3 contributors · Median target $5.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$54.26+$0.15 (+0.28%)
CRISPR Therapeutics AG’s quoted price sits in the lower half of its reported 52-week range, 17.76% below the high.
$28.84+$0.06 (+0.21%)
Beam Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 24.62% below the high.
$13.23-$0.09 (-0.68%)
Intellia Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 28.41% below the high.
$5.24-$0.12 (-2.24%)
Prime Medicine, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.34% below the high.
$8.83+$0.03 (+0.34%)
Benitec Biopharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.06% below the high.
$17.44-$0.10 (-0.57%)
Scribe Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.96% below the high.
$2.54-$0.04 (-1.55%)
Rocket Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 53.39% below the high.
$7.44-$0.03 (-0.4%)
Precision BioSciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.66% below the high.
